The Wolverine Stack: BPC-157 and TB-500 Protocols for Injury Recovery

BPC-157 and TB-500 are two of the most-discussed peptides for musculoskeletal recovery; used together as the "Wolverine Stack," they target healing through distinct but complementary mechanisms — though the human evidence base remains thin.

What These Peptides Are

BPC-157 (Body Protective Compound) is a 15-amino-acid sequence derived from a protein found in human gastric juice. It is not a natural circulating hormone; it is a research compound. Its proposed mechanisms centre on angiogenesis — the formation of new blood vessels — and modulation of nitric oxide signalling, both of which are relevant to tissue repair in tendons, ligaments, and the gut lining.

TB-500 is a synthetic fragment of Thymosin Beta-4, a peptide found in virtually all human and animal cells. Its proposed mechanisms include promotion of cell migration and actin regulation, which together are thought to support tissue remodelling and reduce systemic inflammation. Unlike BPC-157, its effects are described as systemic rather than localised to the injection site.

Mechanisms: What the Research Actually Shows

The mechanism work for both peptides is largely derived from animal models — rodent tendon, ligament, and gut-injury studies. Neither peptide has completed large-scale, randomised controlled trials in humans at the time of writing. This is not a minor caveat: animal pharmacokinetics and dosing do not translate directly to human protocols, and effect sizes observed in rodent studies routinely fail to replicate in human trials across pharmacology broadly.

For BPC-157, the animal literature points to accelerated healing of soft-tissue injuries through upregulation of growth factor receptors and promotion of vascular ingrowth. Nitric oxide pathway involvement has been proposed as a key mediator, though the precise mechanism in humans is unconfirmed.

For TB-500, the cell-migration and actin-binding model is better characterised at the cellular level. Thymosin Beta-4 itself has been studied in some cardiac and wound-healing contexts in humans, but TB-500 as a specific synthetic fragment has a thinner clinical record. The sources used here do not name specific human trials for either peptide, and none are cited here — consistent with the house-style rule against inventing citations.

The rationale for combining them — local repair via BPC-157, systemic inflammation reduction via TB-500 — is mechanistically coherent, but the synergy claim is anecdotal and community-derived rather than trial-supported. One source describes this combination as having "strong anecdotal support and is used widely in the peptide community," which is an accurate characterisation and an honest one: popularity is not evidence.

Standard Protocols Referenced in the Literature

These dosing ranges are drawn from both source articles and represent what is commonly described in the peptide community. They are not clinically validated doses.

Injection site: BPC-157 is commonly injected near the injured tissue, though systemic effects have been proposed. TB-500 is described as strictly systemic — site of injection is not considered critical.

Reconstitution: Both peptides require bacteriostatic water. Rotate injection sites to reduce local irritation. Refrigerate reconstituted peptides and follow supplier guidance on shelf life.

Evidence Gaps — Be Honest With Yourself

Several limitations are worth stating plainly before anyone acts on this information:

• Animal data predominates. The mechanistic claims above come primarily from rodent studies. Human RCT data for these specific compounds does not exist in the public literature at a scale that supports confident dosing or efficacy conclusions.
• No named trials in source material. Neither source article names specific trials, and none are named here. If you encounter articles citing specific effect sizes or trial names for BPC-157 or TB-500 human studies, verify them independently — this is an area where invented or misattributed citations circulate.
• Regulatory status varies. These are research compounds, not approved pharmaceuticals in most jurisdictions. Sourcing, purity, and contamination risk are real concerns. Peptide quality is not standardised across suppliers.
• The "synergy" claim is speculative. The mechanistic logic for combining the two is reasonable, but no comparative trial has tested stack vs. monotherapy vs. placebo in humans.
• Anecdote ≠ data. Wide use in the biohacking and peptide community reflects self-reported outcomes that are uncontrolled, subject to placebo response, and selection-biased toward people who report positive results.

Biomarkers Worth Tracking

If you are using this stack and want to move beyond subjective recovery feel, both source articles suggest monitoring:

• hs-CRP (high-sensitivity C-reactive protein): A systemic inflammation marker. If TB-500's anti-inflammatory claims hold, a downward trend in hs-CRP during a cycle would be an observable signal. Confounders are numerous (diet, sleep, training load), so interpret in context.
• CK (creatine kinase): Elevated CK indicates acute muscle damage or stress. Tracking CK can help distinguish between normal training load and excessive tissue breakdown, and could serve as a rough proxy for recovery status.

A baseline blood draw before starting and a repeat at 8 weeks gives you a within-subject comparison. This is not a clinical endpoint, but it is more informative than anecdote alone. MyKine's biomarker logging can be used to track both markers longitudinally alongside training load and subjective recovery scores.

Practical Takeaway

• BPC-157 and TB-500 target different aspects of recovery — local tissue repair and systemic inflammation respectively — which is why they are stacked, but the synergy claim rests on mechanistic logic and anecdote, not human trial data.
• All meaningful evidence is animal-derived. Translate dosing and effect-size claims from rodent studies to humans with significant caution.
• Standard community protocols are 250–500 mcg BPC-157 once or twice daily near the injury site, and 2.5–5 mg TB-500 twice weekly systemically, for cycles of 4–8 weeks — but these are not clinically validated doses.
• Track hs-CRP and CK before and during a cycle if you want objective data beyond subjective recovery feel.
• Source matters. Peptide purity is unregulated; use a supplier with third-party certificate of analysis and use bacteriostatic water for reconstitution.
• This is not a substitute for medical evaluation of the underlying injury — imaging, physiotherapy, and load management have a stronger evidence base for most musculoskeletal injuries than any peptide stack.

Sources

• Peptide Protocols for Injury Recovery: BPC-157, TB-500 & the Wolverine Stack — MyKine (2026-03-10)
• The Wolverine Stack: Ultimate Recovery Protocol — MyKine (2026-05-16)